Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee

Basic & Clinical Pharmacology & Toxicology
Pertti J Neuvonen

Abstract

This MiniReview is a personal recollection of selected research topics, which the author in collaboration with colleagues has studied, aiming to improve the predictability of drug therapy. In early studies, we found bi- and trivalent cations to reduce the absorption of various tetracyclines and fluoroquinolones. Certain antacids elevated the bioavailability of some non-steroidal anti-inflammatory drugs and sulphonylureas. Various brands of phenytoin tablets revealed great differences in their bioavailability, causing clinical consequences. Numerous factors affecting the antidotal effect of activated charcoal were also studied, with charcoal compared to other gastrointestinal decontamination methods, including ipecac and gastric lavage. Effect of age and diseases on the pharmacokinetics of drugs was a research topic. Acute sotalol intoxications revealed its QT-prolonging properties, and even small mixed overdoses of moclobemide with serotonergic drugs proved fatal. Itraconazole and other potent inhibitors of CYP3A4 could drastically increase exposure to drugs like midazolam, triazolam, buspirone, lovastatin, simvastatin and oxycodone, whereas rifampicin greatly reduced their plasma concentrations. A change from potent inhibition...Continue Reading

References

Jul 1, 1979·Acta Pharmacologica Et Toxicologica·P J NeuvonenL Tarssanen
Jul 1, 1979·British Journal of Clinical Pharmacology·P J NeuvonenR Lehtovaara
May 31, 1978·European Journal of Clinical Pharmacology·P J NeuvonenE Elonen
Sep 23, 1978·British Medical Journal·P J PentikainenE Syvälahti
Dec 19, 1975·European Journal of Clinical Pharmacology·P J NeuvonenK Aho
Dec 19, 1975·European Journal of Clinical Pharmacology·P J PentikäinenS M Elfving
May 1, 1992·Antimicrobial Agents and Chemotherapy·H PeltolaP J Neuvonen
Mar 1, 1992·British Journal of Clinical Pharmacology·P J Neuvonen, K T Kivistö
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·K T KivistöP J Neuvonen
Jan 1, 1992·European Journal of Clinical Pharmacology·K T Kivistö, P J Neuvonen
Jan 1, 1991·European Journal of Clinical Pharmacology·K T Kivistö, P J Neuvonen
Feb 2, 1991·Lancet·D G BaileyJ M Arnold
Aug 1, 1991·British Journal of Clinical Pharmacology·P J Neuvonen, K T Kivistö
Nov 1, 1991·Clinical Pharmacology and Therapeutics·P J NeuvonenP Lehto
Jan 1, 1991·Clinical Pharmacology and Therapeutics·K T Kivistö, P J Neuvonen
Mar 1, 1991·British Journal of Clinical Pharmacology·P J Neuvonen
Dec 1, 1990·British Journal of Anaesthesia·A HillerL Saarnivaara
Jan 1, 1989·Mycoses·J HeykantsG Cauwenbergh
Jan 1, 1988·European Journal of Clinical Pharmacology·P J Neuvonen, K T Kivistö
Jan 1, 1988·Medical Toxicology and Adverse Drug Experience·P J Neuvonen, K T Olkkola
Jul 1, 1986·Human Toxicology·P J Neuvonen, K T Olkkola
May 1, 1985·Clinical Pharmacology and Therapeutics·P J PentikäinenA Penttilä
Aug 23, 1974·European Journal of Clinical Pharmacology·P J Neuvonen, H Turakka
Jun 1, 1974·British Medical Journal·O PenttilåR Lehtovaara
Aug 23, 1974·European Journal of Clinical Pharmacology·P J Neuvonen, O Penttilä
Mar 23, 1974·British Medical Journal·P J Neuvonen, O Penttilä
Nov 28, 1970·British Medical Journal·P J NeuvonenK Björksten
Jan 1, 1983·European Journal of Clinical Pharmacology·P J NeuvonenO Tokola
Jan 1, 1984·European Journal of Clinical Pharmacology·P J Neuvonen, K T Olkkola
Nov 1, 1984·British Journal of Clinical Pharmacology·K T Olkkola, P J Neuvonen
Dec 1, 1984·British Journal of Clinical Pharmacology·R A Tokola, P J Neuvonen
Jan 1, 1984·British Journal of Clinical Pharmacology·R A Tokola, P J Neuvonen
Jan 1, 1984·Acta Pharmacologica Et Toxicologica·P J NeuvonenT Alanen
Nov 1, 1982·Clinical Pharmacokinetics·P J Neuvonen
Apr 1, 1980·European Journal of Clinical Pharmacology·P J PentikäinenK G Jostell
Jul 1, 1982·Clinical Pharmacology and Therapeutics·P J NeuvonenJ Tuomilehto
Jan 1, 1981·European Journal of Clinical Pharmacology·P J NeuvonenM Laakso
Jan 1, 1981·European Journal of Clinical Pharmacology·P J NeuvonenM Kaste
Jan 1, 1980·European Journal of Clinical Pharmacology·P J Neuvonen, E Elonen
Jun 1, 1980·Clinical Pharmacology and Therapeutics·P J NeuvonenM J Mattila
Aug 1, 1980·European Journal of Clinical Pharmacology·J PuurunenO Pelkonen
Jul 1, 1995·Journal of the American Academy of Dermatology·P J Neuvonen, R Suhonen
Aug 1, 1995·Clinical Pharmacology and Therapeutics·S K HukkinenP J Neuvonen

❮ Previous
Next ❯

Citations

Jun 27, 2015·Basic & Clinical Pharmacology & Toxicology·Outi Lapatto-ReiniluotoPertti J Neuvonen
Jan 2, 2016·Pharmacological Reviews·Janne T BackmanPertti J Neuvonen
Aug 26, 2014·Basic & Clinical Pharmacology & Toxicology·Tania Regina PadovaniLuciane Cruz Lopes
Jan 19, 2021·Basic & Clinical Pharmacology & Toxicology·Janne T Backman, Mikko Niemi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Clinical Pharmacology
Tiina KaronenJanne T Backman
Current Pharmaceutical Biotechnology
Zhanglin Ni, Qingcheng Mao
Pharmacology & Therapeutics
Gerard MinuesaJavier Martinez-Picado
Archives of Pharmacal Research
Young Hee ChoiYoon Gyoon Kim
© 2022 Meta ULC. All rights reserved